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The prevention of atherosclerotic cardiovascular diseases is a paramount priority of the 
public health agenda because these diseases are the main cause of death in the 
developed world and an increasing concern in developing countries.1 Many individual 
attitudes about health are shaped by community attitudes, and the recommendations 
given in the clinical practice guidelines for the control of cardiovascular diseases affect 
not only the individual at risk, but the population as a whole. We might consider, for 
example, the current and future impact on National Health System sustainability of the 
recommended treatment needed to prevent a given number of atherosclerotic 
cardiovascular events from occurring. In primary prevention, the recommendation relies 
on the patient’s overall cardiovascular risk profile according to clinical practice 
guidelines.2,3  
Lipid profile management has traditionally played a key role in cardiovascular 
prevention (Figure 1). From the inception of the National Cholesterol Education 
Program, promoted by the National Heart, Blood and Lung Institute, the strategy has 
been focused on the reduction of low-density lipoprotein (LDL) cholesterol in an 
attempt to move its distribution toward the left of the population scale, thus obtaining a 
reduction in total risk. In primary prevention, LDL cholesterol threshold is guided by 
the individual cardiovascular risk profile, whereas in secondary prevention, the current 
LDL cholesterol goal (i.e. <70 mg/dl) is far from being attained for most patients.4,5  
In the current volume of the Journal, Wang et al. make an appeal for a critical appraisal 
of clinical practice guidelines when applying the recommendations in populations 
where interventions have not been properly tested.6 For instance, high quality evidence 
is scarce in Asian populations about the significance of a given lipid parameter on 
overall cardiovascular outcomes as a hard end-point in clinical trials with guaranteed 
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representativeness and adequate sample size. Thus, most clinical recommendations 
applied in Asian countries are derived from guidelines based on clinical trials performed 
in majority Caucasian populations of America and western Europe.2,3  
The manuscript by Wang et al. highlights the need to adapt and rigorously evaluate in a 
recipient population the clinical recommendations developed from evidence observed in 
a different population.6 For example, results from two Asian countries, China and 
Japan, diverged greatly when the IMPACT model was applied to ascertain the role of 
lifestyles and treatments in the changes observed in coronary heart disease mortality. 
China had an increasing mortality trend, explained by rises in total cholesterol reflecting 
an increasingly "Western" diet, while Japan showed a decreasing trend explained by 
policies designed to reduce blood pressure and smoking and encourage evidence-based 
treatment for coronary heart disease.7,8 
In addition, as part of the adaptation process, Wang et al. defend the need to rigorously 
carry out clinical trials with adequate sample size in the very heterogeneous Asian 
populations, not only to ascertain the efficacy of statins treatment but also to extract 
information about patient safety.6 The scientific community agrees that conclusions 
drawn from well-performed clinical trials provide the highest quality of evidence (A 
grade recommendation equivalent). However, clinical trials have known limitations, 
particularly the challenge of representativeness and a short follow-up that does not 
allow assessment of patient safety and the observation of long-term outcomes (i.e. hard 
end-points). These could be remedied in part by pharmacoepidemiology studies using 
real-world data. For instance, two studies conducted in the same electronic medical 
record database from Catalonia (Spain) showed that, in this population, LDL cholesterol 
reduction with statins should remain a priority in primary prevention for individuals at 
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high 10-year coronary risk (10–19.9%) aged 35 to 74 years because of the clear absolute 
benefit in reducing myocardial infarction or ischemic stroke [number-needed-to-treat to 
prevent 1 outcome = 62].9 The authors also point out that their results do not support the 
current clinical practice guidelines2,3 recommending statin treatment without exception 
in patients older than 75 years. In their population, statin treatment in patients aged 75 
or older without type 2 diabetes was not associated with a reduction in atherosclerotic 
cardiovascular disease or in all-cause mortality, even when the incidence of 
atherosclerotic cardiovascular disease was significantly higher than the risk thresholds 
proposed for statin use.10  Both studies had an adequate and representative sample size 
from the Catalan community (617,850 and 46,864 individuals, respectively), long-term 
follow-up (13 and 10 years) and showed that statins did not increase adverse effects in 
the long term.9,10  
As emphasized by the most current clinical practice guidelines and also by Wang et 
al.,2,3,6 the promotion of a healthy lifestyle and risk-factor reduction early in life is key 
to achieve an effective prevention of atherosclerotic cardiovascular diseases.2,3 While 
the worldwide public health agenda must focus on this point, individual countries 
should apply high-quality scientific evidence to validate the guidelines promoted by 
international scientific societies in their own populations.  
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Figure 1. Historical evolution of blood lipid management, according to strategies 
supported by the American and European clinical guidelines.  
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Figure 1. 
 
